Interventional device contract manufacturer Biomerics (Salt Lake City) said it has bought out ATL Technology’s interests in their joint venture, Biomerics ATL LLC, and will rename the business unit Biomerics CRI (BCRI).
The Biomerics/ATL joint venture began in 2018 with the acquisition of assets from Catheter Research Inc. (CRI Medical) and its facilities in Indiana and Costa Rica. CRI was an industry leader in the medical device fluid management market and served several strategic OEM customers out of those facilities, according to Biomerics.
The ATL buyout will expand Biomerics’ presence into Costa Rica and its relationship with CLI’s customers. With the addition of Biomerics CRI, the company will now operate seven business units with more than 1,300 employees.
“Our expansion of operations in Costa Rica is strategic,” said Biomerics CEO Travis Sessions in a news release. “We see great potential in these assets providing high-volume assembly operations. We recently expanded the facility with a new 3,700 square foot cleanroom and are planning an additional 20,000 square foot expansion in 2021.”
In addition to the CRI capabilities, Biomerics provides extrusion, injection molding, high-volume cleanroom assembly, kitting, and packaging services.
Craig England will be president of the new business unit and Anthony Amador will be general manager of the Costa Rica facility. Biomerics CRI employs 200 people across its two locations.All employees have been retained as part of the realignment and will continue operations as usual under the new business entity.